Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary)
Indications Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
Focus Therapeutic Use
Acronyms SAPHIR
Sponsors Fresenius Kabi

Most Recent Events

10 Jun 2024 Planned End Date changed from 30 Sep 2025 to 30 Dec 2025.
16 Apr 2024 Planned End Date changed from 1 Nov 2024 to 30 Sep 2025.
16 Apr 2024 Planned primary completion date changed from 24 Nov 2023 to 30 Sep 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight